Epsilon Healthcare Ltd (ASX: EPN) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Epsilon Healthcare Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$9.73 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
389.10 million
Earnings per share
-0.017
Dividend per share
N/A
Year To Date Return
-24.24%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Epsilon Healthcare Ltd (ASX: EPN)
Latest News
⏸️ Investing
These 3 small cap shares zoomed higher today
⏸️ Investing
Medicinal cannabis shares are smoking the market
⏸️ Investing
Cannabis company Hydroponics Company Ltd sinks 11% lower
⏸️ Investing
Medicinal cannabis shares were smoked on Monday
⏸️ Investing
Will Botanix Pharmaceuticals Ltd burn out?
⏸️ Investing
Medicinal cannabis shares crash lower
⏸️ Investing
Why these 4 ASX shares are starting the week in the red
⏸️ Investing
ASX pot stock update
⏸️ Investing
ALL ORDINARIES finishes higher Wednesday: 8 shares you missed
⏸️ Investing
Hydroponics Company Ltd share price up 5% on Canadian news
⏸️ Investing
Australian pot stocks get smoked
⏸️ Investing
Why these pot stocks are moving higher
EPN ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Epsilon Healthcare Ltd
Epsilon Healthcare Ltd is a diversified healthcare and pharmaceuticals company. It owns number of medicinal cannabis assets including the cannabis manufacturing facility in the Southern Hemisphere, (the Southport Facility) in Southport, Australia and the Tetra Health clinic group. It is engaged in two segments: Contract Development and Manufacturing activities; and Telehealth medical practice services. Contract Development and Manufacturing activities as a CDMO for Australian domiciled and international clients in the area of Active Pharmaceutical Ingredient (API) manufacture and finished formulation production. Key revenue is generated from Contract Development and Manufacturing.
EPN Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 13 Mar 2026 | $0.03 | $0.00 | 0.00% | 3,280 | $0.03 | $0.03 | $0.03 |
| 12 Mar 2026 | $0.03 | $0.00 | 0.00% | 1,177,207 | $0.02 | $0.03 | $0.02 |
| 11 Mar 2026 | $0.02 | $0.00 | 0.00% | 30,000 | $0.02 | $0.02 | $0.02 |
| 10 Mar 2026 | $0.02 | $0.00 | 0.00% | 146,744 | $0.02 | $0.02 | $0.02 |
| 09 Mar 2026 | $0.03 | $0.00 | 0.00% | 264,049 | $0.03 | $0.03 | $0.03 |
| 06 Mar 2026 | $0.03 | $0.00 | 0.00% | 30,893 | $0.03 | $0.03 | $0.03 |
| 05 Mar 2026 | $0.03 | $0.00 | 0.00% | 201,784 | $0.03 | $0.03 | $0.03 |
| 04 Mar 2026 | $0.03 | $0.00 | 0.00% | 51,938 | $0.03 | $0.03 | $0.03 |
| 03 Mar 2026 | $0.03 | $0.00 | 0.00% | 98,156 | $0.03 | $0.03 | $0.03 |
| 02 Mar 2026 | $0.03 | $0.00 | 0.00% | 67,311 | $0.03 | $0.03 | $0.03 |
| 27 Feb 2026 | $0.03 | $0.00 | 0.00% | 43,859 | $0.03 | $0.03 | $0.03 |
| 26 Feb 2026 | $0.03 | $0.00 | 0.00% | 106,776 | $0.03 | $0.03 | $0.03 |
| 25 Feb 2026 | $0.03 | $0.00 | 0.00% | 49,966 | $0.03 | $0.03 | $0.03 |
| 24 Feb 2026 | $0.03 | $0.00 | 0.00% | 219,659 | $0.03 | $0.03 | $0.03 |
| 23 Feb 2026 | $0.03 | $0.00 | 0.00% | 20,036 | $0.03 | $0.03 | $0.03 |
| 20 Feb 2026 | $0.03 | $0.00 | 0.00% | 610,591 | $0.03 | $0.03 | $0.03 |
| 19 Feb 2026 | $0.03 | $0.00 | 0.00% | 10,588 | $0.03 | $0.03 | $0.03 |
| 18 Feb 2026 | $0.03 | $0.00 | 0.00% | 41,169 | $0.03 | $0.03 | $0.03 |
| 17 Feb 2026 | $0.03 | $0.00 | 0.00% | 14,902 | $0.03 | $0.03 | $0.03 |
| 16 Feb 2026 | $0.03 | $0.00 | 0.00% | 77,153 | $0.03 | $0.03 | $0.03 |
| 13 Feb 2026 | $0.03 | $0.00 | 0.00% | 49,752 | $0.03 | $0.03 | $0.03 |
| 12 Feb 2026 | $0.03 | $0.00 | 0.00% | 623,137 | $0.03 | $0.03 | $0.03 |
| 11 Feb 2026 | $0.03 | $0.00 | 0.00% | 241,520 | $0.03 | $0.03 | $0.03 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 08 Jan 2026 | Zoe Hutchings | Buy | 307,934 | $10,856 |
On-market trade. 10,856.78 (including brokerage)
|
| 30 Dec 2025 | Zoe Hutchings | Buy | 519,426 | $19,106 |
On-market trade. including brokerage
|
| 19 Dec 2025 | Zoe Hutchings | Buy | 40,000 | $1,004 |
On-market trade.
|
| 25 Jul 2025 | Alan Beasley | Issued | 10,000,000 | $240,000 |
Issue of options.
|
| 25 Jul 2025 | Peter Giannopoulos | Issued | 25,000,000 | $600,000 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Alan Preston Beasley | Non-Executive DirectorNon-Executive Deputy Chairman | Aug 2016 |
Mr Beasley has over 30 years of experience, having served many company Boards including startups, IPOs and turnarounds. A former director of the Australian subsidiaries of Bankers Trust, Goldman Sachs and BNP Paribas, he has the corporate reach, expertise and experience to advise and assist the company in the corporate and capital markets environment. He also served on the ASX listings appeals committee and thus very familiar with the listing rules and requirements of the ASX, corporate governance and compliance.
|
| Mr Peter Giannopoulos | Chief Executive OfficerExecutive Director | May 2023 |
Mr Giannopoulos brings more than 25 years of experience across the Australian healthcare ecosystems within the ASX healthcare setting and demonstrable accomplishment in leadership, operations, M&A, GMP manufacturing and the delivery of revenue growth opportunities. Previously he was CEO of Cell Therapies Pty Ltd, an Australian based globally active commercial contract development and manufacturing company with a specialisation in cell and gene therapies and cellular immunotherapy products.
|
| Ms Zoe Hutchings | Non-Executive Director | Jun 2024 |
Ms Hutchings has skills acquired in the pharmaceutical and healthcare industry in multi-product franchises, at various product life cycle stages from launch to patent expiry, to established generic portfolios.
|
| Mr Daniel Kaplon | Chief Financial OfficerCompany Secretary | Aug 2025 |
-
|
| Daniel Kaplon | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Watercrest Asset Management Pty Ltd | 35,828,878 | 9.45% |
| Cyrene Holdings Pty Ltd <Cyrene A/C> | 16,771,121 | 4.42% |
| Alexander Hotel Investments Pty Ltd | 16,250,000 | 4.29% |
| Mr Craig Graeme Chapman <Nampac Discretionary A/C> | 10,911,556 | 2.88% |
| HSBC Custody Nominees (Australia) Limited | 10,506,397 | 2.77% |
| Mr Alan Preston Beasley | 10,500,000 | 2.77% |
| Dash & Co Assets Pty Ltd <Dash And Co Super Fund A/C> | 10,000,000 | 2.64% |
| Fennell Church Pty Limited < Fennell Church Prop Unit A/C> | 8,438,499 | 2.23% |
| Health360 Investment Management Inc | 7,052,880 | 1.86% |
| Giannopoulos Superannuation Nominees Pty Ltd <Giannopoulos Super Fund A/C> | 7,000,000 | 1.85% |
| Cannim Group Pty Ltd | 5,555,556 | 1.47% |
| Mr Lloyd Stafford Taylor | 5,318,328 | 1.40% |
| Hollow Sword Blade Company Pty Ltd | 4,000,000 | 1.06% |
| Mr Gary John Radcliff and Mrs Debbi Lee Radcuff | 3,955,700 | 1.04% |
| Barcoo Holdings Pty Ltd <Wyan Family Investments> | 3,795,824 | 1.00% |
| Karantzias Investments Pty Ltd <Karantzias Family A/C> | 3,636,364 | 0.96% |
| BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 3,147,900 | 0.83% |
| Miss Bianca Ngaire Santanna Taylor | 3,011,638 | 0.79% |
| Mr George Daaboul | 3,000,000 | 0.79% |
| Meta Growth Corp | 2,942,489 | 0.77% |